Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FULC Stock Forecast 2026-2027
$3.54
Current Price
$233.22M
Market Cap
Buy 0
Hold 5
Sell 2
Wall St Analyst Ratings
Distance to FULC Price Targets
+408.5%
To High Target of $18.00
-1.1%
To Median Target of $3.50
-15.3%
To Low Target of $3.00
FULC Price Momentum
-6.1%
1 Week Change
+2.6%
1 Month Change
-55.2%
1 Year Change
-68.7%
Year-to-Date Change
-77.5%
From 52W High of $15.74
+25.1%
From 52W Low of $2.83
📊 TOP ANALYST CALLS
Did FULC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Fulcrum Therapeutics is one of their latest high-conviction picks.
Latest FULC Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, FULC has a neutral consensus with a median price target of $3.50 (ranging from $3.00 to $18.00). The overall analyst rating is Hold (5.4/10). Currently trading at $3.54, the median forecast implies a -1.1% downside. This outlook is supported by 0 Buy, 5 Hold, and 2 Sell ratings.
Conversely, the most conservative target is provided by James Condulis at Stifel, suggesting a 15.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FULC Analyst Ratings
0
Buy
5
Hold
2
Sell
FULC Price Target Range
Low
$3.00
Average
$3.50
High
$18.00
Current: $3.54
Latest FULC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FULC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 3, 2026 | JP Morgan | Underweight | Downgrade | $N/A | |
| Jun 2, 2026 | Stifel | James Condulis | Hold | Downgrade | $3.00 |
| Jun 2, 2026 | Piper Sandler | Edward Tenthoff | Underweight | Downgrade | $3.00 |
| Jun 2, 2026 | Truist Securities | Gregory Renza | Hold | Downgrade | $4.00 |
| Jun 2, 2026 | Leerink Partners | Joseph Schwartz | Market Perform | Downgrade | $4.00 |
| Jun 2, 2026 | HC Wainwright & Co. | Andrew S. Fein | Neutral | Downgrade | $3.00 |
| Jan 12, 2026 | JP Morgan | Overweight | Initiates | $N/A | |
| Dec 11, 2025 | Truist Securities | Buy | Maintains | $N/A | |
| Dec 9, 2025 | B of A Securities | Underperform | Maintains | $N/A | |
| Dec 8, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Dec 8, 2025 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Dec 8, 2025 | Piper Sandler | Overweight | Reiterates | $N/A | |
| Dec 8, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 24, 2025 | Truist Securities | Buy | Initiates | $N/A | |
| Nov 24, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 30, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Oct 30, 2025 | Piper Sandler | Overweight | Reiterates | $N/A | |
| Oct 20, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 30, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Jul 29, 2025 | HC Wainwright & Co. | Buy | Upgrade | $N/A |
Fulcrum Therapeutics Inc. (FULC) Competitors
The following stocks are similar to Fulcrum Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Fulcrum Therapeutics Inc. (FULC) Financial Data
Fulcrum Therapeutics Inc. has a market capitalization of $233.22M with a P/E ratio of -2.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -27.1%.
Valuation Metrics
Market Cap
$233.22M
Enterprise Value
$-94,232,376
P/E Ratio
-2.9x
PEG Ratio
0.3x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+141.3%
Current Ratio
34.3x
Debt/Equity
1.8x
ROE
-27.1%
ROA
-18.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Fulcrum Therapeutics Inc. (FULC) Business Model
About Fulcrum Therapeutics Inc.
What They Do
Develops therapies for genetically defined rare diseases.
Business Model
The company operates as a clinical-stage biopharmaceutical firm, focusing on small-molecule therapies that target genetically defined rare diseases. It generates revenue primarily through the development and potential commercialization of its product candidates, which aim to address significant unmet medical needs in rare disease sectors.
Additional Information
Fulcrum Therapeutics, founded in 2015 and based in Cambridge, Massachusetts, utilizes proprietary technology to identify drug targets that modulate gene expression. Its lead product candidate, losmapimod, is aimed at treating facioscapulohumeral muscular dystrophy (FSHD), while other programs target conditions like sickle cell disease and beta-thalassemia. The company is committed to a patient-centered approach, striving to improve the lives of patients and their caregivers.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
55
CEO
Mr. Alexander C. Sapir
Country
United States
IPO Year
2019
Website
www.fulcrumtx.comFulcrum Therapeutics Inc. (FULC) Latest News & Analysis
Latest News
Quick Summary
Fulcrum Therapeutics' stock dropped 50% after the FDA raised safety concerns about the PRC2 inhibitor class, leading to the discontinuation of pociredicr and a strategic review.
Why It Matters
Fulcrum Therapeutics' stock plummeted 50% due to FDA safety concerns over its drug class, signaling potential long-term viability risks and impacting investor confidence significantly.
Source: PRNewsWire
Market Sentiment:
Neutral
Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC)
1 month ago
Quick Summary
Fulcrum Therapeutics, Inc. stock dropped about 50% after the company announced FDA safety concerns leading to the discontinuation of its lead sickle-cell treatment candidate.
Why It Matters
Fulcrum Therapeutics' stock drop reflects investor reaction to regulatory setbacks, indicating increased risk and uncertainty, which could impact future funding and development prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
1 month ago
Quick Summary
Fulcrum Therapeutics (FULC) is currently in oversold territory, suggesting potential for a trend reversal, supported by analysts revising earnings estimates higher.
Why It Matters
Fulcrum Therapeutics may be poised for a rebound due to oversold conditions and bullish analyst revisions, suggesting potential upside for investors.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Fulcrum Therapeutics' shares fell 50% in premarket trading after it halted development of its sickle-cell disease drug due to FDA cancer-risk concerns and is considering a sale or merger.
Why It Matters
Fulcrum Therapeutics' 50% stock drop signals lost investor confidence due to halted drug development and potential restructuring, impacting future growth and valuation.
Source: Reuters
Market Sentiment:
Negative
Quick Summary
Fulcrum Therapeutics (NASDAQ: FULC) shares rose despite the company discontinuing pociredir, its lead drug for sickle cell disease, indicating market volatility amid challenges.
Why It Matters
Fulcrum's decision to discontinue its lead drug raises concerns about future revenue and growth, impacting investor confidence and stock performance.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Holzer & Holzer, LLC is investigating Fulcrum Therapeutics (NASDAQ: FULC) for potential federal securities law violations after it discontinued its pociredir program, causing a stock price drop.
Why It Matters
Fulcrum's discontinuation of a key treatment program and the subsequent stock price drop signal potential regulatory issues, impacting investor confidence and future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About FULC Stock
What is Fulcrum Therapeutics Inc.'s (FULC) stock forecast for 2027?
Based on our analysis of 6 Wall Street analysts, Fulcrum Therapeutics Inc. (FULC) has a median price target of $3.50. The highest price target is $18.00 and the lowest is $3.00.
Is FULC stock a good investment in 2027?
According to current analyst ratings, FULC has 0 Buy ratings, 5 Hold ratings, and 2 Sell ratings. The stock is currently trading at $3.54. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FULC stock?
Wall Street analysts predict FULC stock could reach $3.50 in the next 12 months. This represents a -1.1% decrease from the current price of $3.54. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fulcrum Therapeutics Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical firm, focusing on small-molecule therapies that target genetically defined rare diseases. It generates revenue primarily through the development and potential commercialization of its product candidates, which aim to address significant unmet medical needs in rare disease sectors.
What is the highest forecasted price for FULC Fulcrum Therapeutics Inc.?
The highest price target for FULC is $18.00 from at , which represents a 408.5% increase from the current price of $3.54.
What is the lowest forecasted price for FULC Fulcrum Therapeutics Inc.?
The lowest price target for FULC is $3.00 from James Condulis at Stifel, which represents a -15.3% decrease from the current price of $3.54.
What is the overall FULC consensus from analysts for Fulcrum Therapeutics Inc.?
The overall analyst consensus for FULC is neutral. Out of 6 Wall Street analysts, 0 rate it as Buy, 5 as Hold, and 2 as Sell, with a median price target of $3.50.
How accurate are FULC stock price projections?
Stock price projections, including those for Fulcrum Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 2:46 AM UTC